Angiogenic switch in multiple myeloma.
Angiogenesis is the hallmark of cancer. Growing evidence indicates that an imbalance between pro- and anti-angiogenic molecules triggers the angiogenic switch during tumor progression. Several molecules, able to affect vascular formation and function, are now beginning to be elucidated. Recent data indicate that angiogenesis also occurs in hematological malignancies. In multiple myeloma it has been demonstrated that patients with active disease have an increase in bone marrow angiogenesis correlated with the progression of disease and an adverse prognosis. The pathophysiology of myeloma-induced angiogenesis is complex and involves either the direct production of angiogenic molecules by myeloma cells or their induction in the microenvironment. In this review we have focalized our attention on the main factors involved in the angiogenic switch that occurs in MM patients.
Giuliani
Nicola
N
Chair of Hematology and BMT Center, University of Parma, Parma, Italy. n_giuliani@yahoo.com
Colla
Simona
S
Rizzoli
Vittorio
V
D042501:Angiogenic Proteins / Q000096:biosynthesis; D001853:Bone Marrow / Q000503:physiopathology*; D015973:Gene Expression Regulation, Leukemic / Q000502:physiology; D006801:Humans; D009101:Multiple Myeloma / Q000503:physiopathology*; D009389:Neovascularization, Pathologic / Q000503:physiopathology*
D042501:Angiogenic Proteins